Advertisement

Obesity Surgery

, Volume 20, Issue 6, pp 685–691 | Cite as

A Noninvasive Clinical Scoring Model Predicts Risk of Nonalcoholic Steatohepatitis in Morbidly Obese Patients

  • Alex Ulitsky
  • Ashwin N. Ananthakrishnan
  • Richard Komorowski
  • James Wallace
  • Sri Naveen Surapaneni
  • Jose Franco
  • Kia Saeian
  • Samer GawriehEmail author
Clinical Research

Abstract

Background

A simple model to predict nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease is desirable to optimize the selection of patients for liver biopsy. We investigated a large group of morbidly obese patients to derive a scoring system based on simple clinical and laboratory variables.

Methods

Consecutive subjects undergoing bariatric surgery and without evidence of other liver disease or significant alcohol use underwent intraoperative liver biopsy. Demographic, clinical, and biochemical variables were collected. A scoring model was derived using variables found to be independent predictors of NASH. The scores were divided into four risk categories (low, intermediate, high, and very high). Positive and negative predictive values (PPV/NPV) were derived for each category and the area under the receiver operator curve (AUROC) was calculated.

Results

A total of 253 subjects were included: 52 (20.6%) had NASH, 116 (45.8%) had simple steatosis, and 85 (33.6%) had normal liver histology. Only ten subjects (19% of NASH group) had significant (≥ stage 2) fibrosis. Multivariate analysis identified diabetes, abnormal ALT, and hypertriglyceridemia as independent predictors of NASH. Sleep apnea showed a strong trend toward significance and was also included in the model. This model showed a NPV of 89.7% in the low risk category and a PPV of 75% in the very high risk category, with AUROC of 0.76.

Conclusions

A simple scoring system performs well in predicting NASH and can be used in the clinic to optimize the selection of morbidly obese patients for liver biopsy.

Keywords

NASH Morbid obesity Predictive model Liver biopsy NAFLD Hepatosteatosis 

References

  1. 1.
    Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2(12):1048–58.CrossRefPubMedGoogle Scholar
  2. 2.
    Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28(4):339–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–31.CrossRefPubMedGoogle Scholar
  5. 5.
    Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344(7):495–500.CrossRefPubMedGoogle Scholar
  7. 7.
    Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91–100.CrossRefPubMedGoogle Scholar
  9. 9.
    Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15(3):310–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Spaulding L, Trainer T, Janiec D. Prevalence of non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass. Obes Surg. 2003;13(3):347–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.CrossRefPubMedGoogle Scholar
  12. 12.
    Campos GM, Bambha K, Vittinghoff E, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47(6):1916–23.CrossRefPubMedGoogle Scholar
  13. 13.
    Harnois F, Msika S, Sabate JM, et al. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2006;16(2):183–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Wong VW, Wong GL, Tsang SW, et al. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther. 2009;29(4):387–96.CrossRefPubMedGoogle Scholar
  15. 15.
    Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94(4):1018–22.CrossRefPubMedGoogle Scholar
  17. 17.
    Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30(6):1356–62.CrossRefPubMedGoogle Scholar
  18. 18.
    Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 Jun;7:1224–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Amarapurka DN, Amarapurkar AD, Patel ND, et al. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann Hepatol. 2006;5(1):30–3.PubMedGoogle Scholar
  20. 20.
    Gholam PM, Flancbaum L, Machan JT, et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102(2):399–408.CrossRefPubMedGoogle Scholar
  21. 21.
    Abrams GA, Kunde SS, Lazenby AJ, et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology. 2004;40(2):475–83.CrossRefPubMedGoogle Scholar
  22. 22.
    Kallwitz ER, Guzman G, TenCate V, et al. The histologic spectrum of liver disease in African-American, non-Hispanic White, and Hispanic obesity surgery patients. Am J Gastroenterol. 2009;104(1):64–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Sorrentino P, Tarantino G, Conca P, et al. Silent non-alcoholic fatty liver disease—a clinical-histological study. J Hepatol. 2004;41(5):751–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40 Suppl 1:S5–10.PubMedGoogle Scholar
  25. 25.
    Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2(3):262–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Brunt EM, Kleiner DE, Wilson LA, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49(3):809–20.CrossRefPubMedGoogle Scholar
  27. 27.
    Friis-Liby I, Aldenborg F, Jerlstad P, et al. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. 2004;39(9):864–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis. 2009;203(2):581–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2010

Authors and Affiliations

  • Alex Ulitsky
    • 4
  • Ashwin N. Ananthakrishnan
    • 4
  • Richard Komorowski
    • 1
  • James Wallace
    • 2
  • Sri Naveen Surapaneni
    • 4
  • Jose Franco
    • 4
  • Kia Saeian
    • 4
  • Samer Gawrieh
    • 4
    • 3
    Email author
  1. 1.Division of Surgical Pathology, Department of PathologyMedial College of WisconsinMilwaukeeUSA
  2. 2.Department of SurgeryMedial College of WisconsinMilwaukeeUSA
  3. 3.Zabocki VA Medical CenterMilwaukeeUSA
  4. 4.Division of Gastroenterology and Hepatology, Department of MedicineMedical College of WisconsinMilwaukeeUSA

Personalised recommendations